Latest news

  • 14 February 2018

    Sensorion Presents New SENS-401 Data at ARO 2018 MidWinter Meeting. Read

  • 13 February 2018

    Sensorion: modification de  l'agenda financier 2018. Read (In French only) Sensorion : Modification de l’agenda financier 2018

  • Company

    Sensorion combines world-class, scientific excellence and top-tier execution capabilities to deliver first-in-class therapeutics as a “pure player” focused on debilitating inner ear disorders. Read more

  • Pipeline

    Sensorion has two products in clinical trials, and with our efficient, in-house technology platform, we are well positioned to deliver and expand our pipeline. Read more

  • Investors

     Sensorion is focused on addressing treatment needs for 140 million of patients suffering from debilitating inner ear disorders having limited treatment options. Read more